Is a GLP-1 worth the money?

That is not a question a comparison site can answer for someone, but it can supply the arithmetic: $98 a month at the cheapest verified route is roughly $1,274 across a year of thirteen fills. Whether the trial figures justify that depends on the indication, the coverage and the person.

What is the strongest argument against starting one?

Cost combined with open-endedness. Not the side effects — those are documented, mostly gastrointestinal and mostly worst after a dose step. The harder problem is that the price recurs indefinitely and the cash route builds nothing toward a plan's out-of-pocket cap.

Are the cheaper compounded versions the same thing?

The same molecule where the pharmacy uses semaglutide base, and not the same product: no FDA review of that formulation, no inspection to the approved standard, and a legal status under active litigation.

← All providers and medications

The case for and against a GLP-1

The honest version of this list is shorter than most and has numbers in it. What follows is drawn from the labels, the named trials and the prices verified on this site — not from a balance of opinions.

Last updated 2026-08-24 — the prices and figures quoted below

What are the pros and cons of GLP-1 drugs?

The trial figures are the strongest thing in their favour and they are large: Zepbound 20.9%, Wegovy pill 16.6%, Mounjaro 15% mean weight loss, each in the trial its own label cites. Those trials also measured things people do not search for and that matter more than the scale: Wegovy's label carries a cardiovascular indication, and Zepbound carries one for moderate to severe obstructive sleep apnea. Where one of those applies, the drug is coverable under a plan that refuses it for weight alone — which changes the price question completely. Verified cash prices on this site run $98 to $499 a month, and a year is not twelve times a month: the early months are a different dose at a different price, and Lilly and Novo each bill a 28-day month, which makes a year thirteen fills. The cash price also buys nothing toward a deductible or an out-of-pocket maximum, because it sits outside the plan entirely. And the conditional self-pay rates are conditional: miss a refill window and the higher doses re-price. Every GLP-1 in this class carries a boxed warning for thyroid C-cell tumours, seen in rodents, with the human relevance not determined — which is what the label says rather than a reassurance or an alarm.

What they do, measured

The trial figures are the strongest thing in their favour and they are large: Zepbound 20.9%, Wegovy pill 16.6%, Mounjaro 15% mean weight loss, each in the trial its own label cites.

Those trials also measured things people do not search for and that matter more than the scale: Wegovy's label carries a cardiovascular indication, and Zepbound carries one for moderate to severe obstructive sleep apnea. Where one of those applies, the drug is coverable under a plan that refuses it for weight alone — which changes the price question completely.

What they cost, which is the largest con

Verified cash prices on this site run $98 to $499 a month, and a year is not twelve times a month: the early months are a different dose at a different price, and Lilly and Novo each bill a 28-day month, which makes a year thirteen fills.

The cash price also buys nothing toward a deductible or an out-of-pocket maximum, because it sits outside the plan entirely. And the conditional self-pay rates are conditional: miss a refill window and the higher doses re-price.

What the labels warn about

Every GLP-1 in this class carries a boxed warning for thyroid C-cell tumours, seen in rodents, with the human relevance not determined — which is what the label says rather than a reassurance or an alarm. Contraindications include a personal or family history of medullary thyroid carcinoma and MEN 2.

The common reactions are gastrointestinal and cluster just after a dose increase rather than at a steady dose: nausea, diarrhoea, vomiting, constipation. Pancreatitis and gallbladder disease appear in the serious lists. The per-drug pages quote each label in full rather than summarising across them.

The two cons nobody writes on the pro side

It is not a course with an end. The pricing is built around continuing refills, and what happens on stopping is the question the trials that measured regain were designed to answer. Planning around a year of it and then stopping is a different decision from planning around it indefinitely.

And the cheap route is cheap for a reason. Compounded versions cost a fraction and are not FDA approved or reviewed; the exemption they are made under is being litigated, and a pharmacy that is enjoined stops shipping to the people relying on it.

Every price, ranked →What a year actually costs →What a pharmacy pays →FDA warning letters →What a GLP-1 is, and what each one costs →GLP-1 vs GLP-3 →Is compounded semaglutide safe? →

Questions

Is a GLP-1 worth the money?: That is not a question a comparison site can answer for someone, but it can supply the arithmetic: $98 a month at the cheapest verified route is roughly $1,274 across a year of thirteen fills. Whether the trial figures justify that depends on the indication, the coverage and the person.
What is the strongest argument against starting one?: Cost combined with open-endedness. Not the side effects — those are documented, mostly gastrointestinal and mostly worst after a dose step. The harder problem is that the price recurs indefinitely and the cash route builds nothing toward a plan's out-of-pocket cap.
Are the cheaper compounded versions the same thing?: The same molecule where the pharmacy uses semaglutide base, and not the same product: no FDA review of that formulation, no inspection to the approved standard, and a legal status under active litigation.

Every figure above is read from the drug's own card, which records where it came from and the date it was verified. Clinical statements are quoted from the FDA label or the named trial, never interpreted. Information only, not medical advice.